Marquette Asset Management LLC Lowers Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Marquette Asset Management LLC lowered its holdings in shares of Chimerix, Inc. (NASDAQ:CMRX) by 6.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,986 shares of the biopharmaceutical company’s stock after selling 7,023 shares during the quarter. Marquette Asset Management LLC’s holdings in Chimerix were worth $379,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in Chimerix in the 2nd quarter worth approximately $137,000. Valeo Financial Advisors LLC lifted its holdings in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 138,098 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Institutional investors own 45.42% of the company’s stock.

Chimerix Stock Performance

NASDAQ CMRX opened at $3.37 on Wednesday. The stock has a 50 day moving average price of $2.11 and a 200-day moving average price of $1.32. Chimerix, Inc. has a one year low of $0.75 and a one year high of $3.80. The company has a market capitalization of $303.08 million, a P/E ratio of -3.59 and a beta of 0.36.

Wall Street Analysts Forecast Growth

CMRX has been the topic of several research analyst reports. Wedbush reiterated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Chimerix in a report on Monday, December 30th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.